Dialysis News and Research

Latest Dialysis News and Research

Argon gets FDA clearance to market OptionELITE IVC filter over-the-wire delivery technique

Argon gets FDA clearance to market OptionELITE IVC filter over-the-wire delivery technique

New study examines factors that may lead to end stage renal disease

New study examines factors that may lead to end stage renal disease

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

FDA approves Farxiga tablets to improve glycemic control in adults with type 2 diabetes mellitus

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Proteon's PRT-201 gets orphan drug designation for prevention of arteriovenous access dysfunction

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Blood conservation strategy during AVR can reduce costs, complications

Blood conservation strategy during AVR can reduce costs, complications

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

EMA accepts Otsuka's marketing authorisation application for tolvaptan for treatment of ADPKD

ICSA awards 2014 ONC HIT certification to Acumen EHR system

ICSA awards 2014 ONC HIT certification to Acumen EHR system

Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

Holiday reads: Squabbling families, the psychology of Santa, holiday stress and chocolate chip cookies

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

Janssen receives complete response letter for canagliflozin/metformin FDC therapy for type 2 diabetes

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

FDA accepts Shield Therapeutics' IND application to begin ST10 Phase 3 pivotal study for IDA treatment

Market research report on global and China insulin industry

Market research report on global and China insulin industry

FDA grants indication for GORE VIABAHN Endoprosthesis to treat thrombotic occlusion

FDA grants indication for GORE VIABAHN Endoprosthesis to treat thrombotic occlusion

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

JCB Laboratories installs Lighthouse monitoring system to improve patient safety

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Siemens Healthcare to introduce new angiography system at RSNA 2013

Siemens Healthcare to introduce new angiography system at RSNA 2013

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.